What is FG-3019?

Category: Others

Most popular types: IPF Phase II FG-3019 Trial


FG-3019 is fully human recombinant IgG/kappa monoclonal anti-body being evaluated for the treatment of chronic kidney disease (CKD), fibrotic diseases, and certain metastatic cancers.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 1
None 1

Commonly reported side effects and conditions associated with FG-3019

Side effect Patients
Fatigue 1

Why patients stopped taking FG-3019

Multiple reasons could be selected

Reason Patients
Other 1
See 1 patient who's stopped using FG-3019


Stopped using FG-3019

Duration Patients
2 - 5 years 1
Adherence Evaluations
Always 2
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 1
Not at all hard to take 1
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 1
Last updated:
There are no evaluations for FG-3019.